ANN ARBOR, Mich., Sept. 11, 2013 /PRNewswire/ -- NanoBio Corporation today announced that the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting showing the safety and efficacy of a nanoemulsion (NE) adjuvanted intramuscular vaccine for the prevention of respiratory syncytial virus (RSV). RSV plagues nearly all children by the age of three and can be life-threatening for premature babies, children with other health conditions, and the elderly. Currently, a vaccine for the prevention of RSV is not commercially available.
NanoBio will also present data at the conference demonstrating the benefits of its NE adjuvant in the development of an effective intramuscular herpes simplex virus-2 (HSV-2) vaccine. HSV-2 is a leading cause of genital herpes, a sexually transmitted disease affecting over 45 million people in the U.S.
NanoBio’s NanoStat® technology platform serves as the foundation for the RSV and HSV-2 vaccines recently evaluated in the company’s pre-clinical studies. The NanoStat platform utilizes a novel oil-in-water nanoemulsion that is inherently antimicrobial and that can effectively adjuvant a broad spectrum of vaccine antigens. As such, the NE adjuvant can inactivate, split and adjuvant whole viruses to enable vaccines that elicit robust neutralizing immunity and broad protection. In the case of RSV and HSV-2, the company’s NanoStat vaccines therefore leverage the full repertoire of antigens in each virus to confer better protection against the disease.
“The pre-clinical results being presented at ICAAC demonstrate the significant potential for NE adjuvanted vaccines to safely and effectively prevent disease. Since the NanoStat adjuvant is antimicrobial in and of itself, we can use it to inactivate a whole pathogen and thereby create a highly effective vaccine,” said Ali Fattom, NanoBio’s Senior Vice President of Vaccine Research. “In this way, we can avoid using chemicals like formalin or beta-Propiolactone that can alter the antigens present in a pathogen. The NE adjuvant therefore allows us to present the complete set of epitopes from a virus to the immune system in their native state, in order to elicit robust immunity.”
The company is currently testing its NanoStat adjuvant in vaccines for several respiratory and sexually transmitted diseases including anthrax, HIV, HSV-2, pandemic influenza, and RSV. The NE adjuvant has been shown to be safe and immunogenic in prior human clinical trials for seasonal influenza.
Following are details of the studies NanoBio and its research collaborators will present at the ICAAC meeting in Denver, CO:
- Poster session on September 11, 2013 (11:00 a.m. 1:00 p.m.), Exhibit Hall A: Novel Intramuscular Nanoemulsion Adjuvanted HSV2 Vaccine Protects Guinea Pigs
- Oral presentation on September 12, 2013 (3:00 5:30 p.m.), Room 503: High Affinity Neutralizing Activity Associated with Immunogenicity and Protection Following Intramuscular Administration of a Novel W805EC Nanoemulsion Adjuvanted RSV Vaccine in Cotton Rats.
For additional information, please visit NanoBio and/or ICAAC 2013.
About NanoBio
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company’s NanoStat technology platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan. For more information on NanoBio or its products, please visit the www.nanobio.com.
Contact:
Schwartz MSL
Stacey Holifield / Danielle Sullivan
NanoBio@SchwartzMSL.com
(781) 684-0770
SOURCE NanoBio Corporation
Help employers find you! Check out all the jobs and post your resume.
